Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN
- PDF / 1,202,963 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 21 Downloads / 150 Views
PSORIATIC ARTHRITIS (J SCHER, SECTION EDITOR)
Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN Stacie Bell 1 & Joseph F. Merola 2 & Dan E. Webster 3 & Stephen R. Pennington 4 & Wilson Liao 5 & Alexis Ogdie 6 & Oliver FitzGerald 4 & Christopher Ritchlin 7 & Jose U. Scher 8
# Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Purpose of Review To provide a general overview of the organizations dedicated to advance clinical and translational research in the field of psoriatic disease and to describe the current and future opportunities for team science approaches to overcome unmet needs in the field. Descriptions of initiatives from the NPF, PPACMAN, and GRAPPA are summarized. Recent Findings Program projects have recently identified areas of knowledge gaps in diagnosis, treatment, and prevention of psoriasis and psoriatic arthritis (PsA). NPF’s Psoriasis Prevention Initiative aims to identify interventions that can prevent the onset and relapse of psoriatic disease or related comorbidities. The Psorcast Study is a joint venture between PPACMAN and Sage Bionetworks based on patient-generated smartphone measurements of psoriatic disease. Similarly, GRAPPA is involved in a number of projects related to axial PsA, enthesitis prevalence, and biomarker discoveries. Summary As important initiatives bring new targets for diagnosis and therapeutics in psoriatic disease, supra-endeavors such as the NIH-Accelerating Medicines Partnership (AMP) and the European Innovative Medicines Initiative (IMI) are promising public-private partnerships that can significantly catapult the field forward. Keywords Psoriasis . Psoriatic arthritis . Prevention . Cure . Precision medicine
Introduction The field of psoriatic disease has matured substantially over the last decade as manifested by the revolutionary advances in therapeutics that dramatically improve psoriasis of the skin and the recognition of new and refined outcomes research tools. However, and despite substantial improvement in treatment options for psoriatic arthritis (PsA) over the last decade,
up to 60% of patients do not respond adequately to a wide range of therapies. Moreover, two-thirds of patients with psoriasis and musculoskeletal symptoms have never been evaluated by a rheumatologist. To address these major barriers, multiple clinical and translational investigators are proposing novel therapeutic approaches to achieve better outcomes (remission and even cure) as well as pre-clinical intervention strategies centered on treating psoriasis patients at increased
This article is part of the Topical Collection on Psoriatic Arthritis * Jose U. Scher [email protected] 1
National Psoriasis Foundation, Portland, OR, USA
2
Department of Medicine, Division of Rheumatology, and Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
3
Sage Bionetworks, Seattle, WA, USA
4
Conway Institute of Biomedical Research, University College Dublin,
Data Loading...
